Product category:
Ultrasound equipment and ultrasonic spectroscopy
News Release from: Akubio
Edited by the Laboratorytalk Editorial
Team on 25 September 2003
Label-free sensing technology acquired
Deal with GSK to obtain the worldwide rights to the intellectual property, equipment and know how related to piezoelectric crystal microbalance sensor system
Akubio, an acoustic detection company, has concluded a deal with GlaxoSmithKline (GSK) to obtain the worldwide rights to the intellectual property, equipment and know how related to GSK's piezoelectric crystal microbalance sensor system GSK Ventures (GSK's intellectual property based venture fund) selected Akubio following an active search for a company to commercialise the label-free technology and in return for the rights has taken an equity stake in Akubio
This article was originally published on Laboratorytalk on 24 Jul 2003 at 8.00am (UK)
Related stories
Acoustic technology granted US patent
Revolutionary system can sensitively, rapidly and economically detect analytes in complex fluids such as serum without the need for radio-, enzymatic or fluorescent labels
Acoustic analysis of biomolecular interactions
Based on resonant acoustic profiling (Rap), Rapid4 enables real-time label-free measurement and analysis of biomolecular interactions with the highest level of accuracy reproducibility and sensitivity
The GSK system is complementary to Akubio's Rupture Event Scanning (Revs) and Resonant Acoustic Profiling (Rap) system, and will allow increased sensitivity and improved performance of the acoustic resonator, central to Akubio's technology.
Revs uses sensitive acoustic technology to detect the sound of bonds breaking as molecules are shaken off a vibrating resonator.
In Rap this is coupled with fluid delivery systems to allow the sensitive and rapid detection of analytes in a complex fluid in real time, without the need for the radio-, enzymatic or fluorescent labels used currently.
The agreement includes the assignment of two pending patent applications, in the USA, Europe, and other selected countries.
John Pritchard, CEO of Akubio, said: "GSK's system is a perfect complement to our founding label-free technologies and this acquisition strengthens and widens our IP position.
"The fact that GSK selected Akubio as its partner to commercialise this technology is a testament to our leading position in acoustic detection technology.
"This technology presents significant advantages over currently available small molecule sensing techniques".
• Akubio: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
